News Search Results

Displaying Results 576-600 of 4568 "biotechnology"

Jun 01, 2026, 08:00 ET Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis

full Prescribing Information for ZAYNICH™.About WockhardtWockhardt is a global pharmaceutical and biotechnology company focused on developing innovative anti-infective solutions. With a legacy of scientific excellence and a mission to combat antimicrobial

More news about: Wockhardt


Jun 01, 2026, 07:00 ET Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration

www.biondbio.comAbout GIBF (Guangzhou-Israel Biotechnology Fund)The Guangzhou-Israel Biotechnology Fund (GIBF) is a specialized life science investment fund focused on advancing innovative biotechnology companies and technologies through strategic investment and development

More news about: Biond Biologics Ltd.; GIBF


Jun 01, 2026, 07:00 ET Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

CAMBRIDGE, Mass., June 1, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a pre-clinical-stage biotechnology company pioneering a new category of antivirals, today announced the execution of a strategic development initiative designed to support the advancement

More news about: Decoy Therapeutics, Inc


Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

rapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced results from the twelve-month interim analysis

More news about: Skyhawk Therapeutics


Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease

rapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced results from the twelve-month interim analysis

More news about: Skyhawk Therapeutics


Jun 01, 2026, 04:21 ET Kimera Labs Implements ISO 9001:2015, ISO 13485:2016, and ISO 22716:2007 Across Its Miramar Manufacturing Facility

MIRAMAR, Fla., June 1, 2026 /PRNewswire/ -- Kimera Labs, Inc., a clinical-stage biotechnology company specializing in the research and manufacture of placental mesenchymal stem cell-derived exosomes, today announced the integration of three

More news about: Kimera Labs Inc


Jun 01, 2026, 04:00 ET ZIM Board of Directors Appoints Dr. Chen Lichtenstein as President and CEO of the Company; will also be joining its Board of Directors

Directors at Teva Pharmaceuticals Ltd., as chairman of the board of directors at international companies in the fields of environmental sciences and biotechnology and as a senior advisor to international investment entities. Dr. Lichtenstein holds joint doctoral degrees from the Graduate School of Business

More news about: ZIM Integrated Shipping Services Ltd.


Jun 01, 2026, 03:00 ET LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position

remaining a core member of the leadership team at LUCENT. LUCENT was founded in 2022 by Goodman, providing specialist Medical Affairs support to biotechnology and pharmaceutical companies across the US, UK and Europe. As LUCENT enters its next phase of growth, this leadership change will ensure the continued

More news about: LUCENT Biopharma Ltd


May 31, 2026, 23:51 ET Aphranel® MagiCCrystal CaHA Filler obtient la certification MDR de l'UE en tant qu'injectable régénérateur de première qualité

SHANGHAI, 1er juin 2026 /PRNewswire/ -- Moyom Biotechnology a annoncé que son produit haut de gamme dédié à l'esthétique régénérative, Aphranel® MagiCCrystal CaHA Filler, a officiellement obtenu la certification au titre du règlement de l'Union européenne sur

More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel


May 31, 2026, 23:50 ET Aphranel® MagiCCrystal CaHA Filler erhält die EU MDR-Zertifizierung als hochwertiges regeneratives Injektionsmittel

SHANGHAI, 1. Juni 2026 /PRNewswire/ -- Moyom Biotechnology gab bekannt, dass sein hochwertiges Produkt für regenerative Ästhetik, Aphranel® MagiCCrystal CaHA Filler, am 18. Mai 2026 offiziell die Zertifizierung nach der Medizinprodukteverordnung der Europäischen

More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel


May 31, 2026, 22:37 ET ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential

reach of our technology and deliver hope to patients worldwide."About Oricell TherapeuticsOricell is a clinical-stage global biotechnology company dedicated to becoming a pioneer in tumor immunotherapy. Focused on solving unmet medical needs in oncology and immunology, by powering a

More news about: Oricell Therapeutics Holdings Limited


May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

SHANGHAI, May 31, 2026 /PRNewswire/ -- D3 Bio Inc., a global clinical-stage biotechnology company dedicated to developing innovative oncology therapeutics, announced first-line (1L) clinical data of elisrasib

More news about: D3 Bio


May 31, 2026, 20:00 ET ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

administration including intratumoral, intracavitary and intravenous administrations.About ImmViraImmVira is a clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization

More news about: ImmVira Group


May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:

More news about: Eli Lilly and Company


May 30, 2026, 06:36 ET Chandigarh University Research Scientist Receives Startup Research Grant of Rs 24 Lakhs

Giving fillip to the cutting-edge research in crop biotechnology and sustainable agriculture, the research faculty and students at Chandigarh University's University Centre for Research & Development (UCRD) and University Institute of Biotechnology (UIBT) are making significant contributions in the

More news about: Chandigarh University


May 29, 2026, 16:01 ET AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic

More news about: Amgen


May 29, 2026, 12:28 ET Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets

products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position

More news about: Lupin Pharmaceuticals, Inc.


May 29, 2026, 11:00 ET Colorectal Cancer Alliance and GCAR Announce Collaboration to Advance a Groundbreaking Adaptive Clinical Trial Platform for Colorectal Cancer: KLEOS

Society of Clinical Oncology Annual Meeting to advance the vision of the KLEOS adaptive clinical trial platform.Pharmaceutical and biotechnology partners are invited to connect with GCAR and the Colorectal Cancer Alliance at the American Society of Clinical Oncology Annual Meeting

More news about: Global Coalition for Adaptive Research


May 29, 2026, 10:45 ET Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight Loss

NORTHBROOK, Ill., May 29, 2026 /PRNewswire/ -- Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced

More news about: Kalohexis


May 29, 2026, 08:00 ET SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund

investment.The Korea Growth Fund is a public-private policy financing initiative established to foster strategic industries such as AI, semiconductors, biotechnology, and secondary batteries. Structured as a citizen-participation investment fund, it aims to provide long-term capital to future growth industries.

More news about: SK bioscience


May 29, 2026, 07:00 ET Alaw Therapeutics Announces Two Major Pipeline Milestones Advancing Brain-Penetrant CDK Oncology Programs

SAN DIEGO, May 29, 2026 /PRNewswire/ -- Alaw Therapeutics, Inc. ("Alaw"), a clinical-stage biotechnology company developing precision oncology therapeutics designed to control oncogenic proliferation, tumor survival, and therapeutic resistance, today

More news about: Alaw Therapeutics


May 29, 2026, 06:00 ET Harbinger Health Presents Clinical Data at ASCO Supporting RESOLVE™ as a New Blood-Based Category for Evaluation of Suspected Cancer

Harbinger Health, a biotechnology company pioneering cancer resolution, today announced the presentation of clinical data on Harbinger's multi-cancer detection test in symptomatic

More news about: Harbinger Health


May 29, 2026, 02:28 ET Aphranel® MagiCCrystal obtiene la certificación EU MDR

calidadSHANGHÁI, 29 de mayo de 2026 /PRNewswire/ -- Moyom Biotechnology dio a conocer hoy que su producto prémium de estética regenerativa, Aphranel® MagiCCrystal CaHA Filler, ha conseguido oficialmente la certificación

More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel


May 28, 2026, 18:09 ET Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D., Chief

More news about: Kodiak Sciences Inc.


May 28, 2026, 13:00 ET Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:

More news about: Eli Lilly and Company


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.